Novartis’ CDK Inhibitor May Benefit From Swing Back To Single-Arm Trials
Executive Summary
As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.
You may also be interested in...
Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio
Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.
Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio
Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.
The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.